Printer Friendly

MEDIMMUNE BEGINS STUDY OF CYTOGAM IN AIDS PATIENTS

 MEDIMMUNE BEGINS STUDY OF CYTOGAM IN AIDS PATIENTS
 GAITHERSBURG, Md., March 31 /PRNewswire/ -- MedImmune, Inc.


(NASDAQ: MEDI) announced today the start of a combined Phase I/II study of CytoGam (TM), the company's cytomegalovirus (CMV) immune globulin, in patients with HIV infection. Retinitis due to CMV is the major cause of blindness in AIDS patients.
 The study, expected to be completed by September 1992, is designed to determine the safety and pharmacokinetics of CytoGam in AIDS patients. The study is intended to provide information on the level and duration of CMV antibodies achieved by CytoGam infusion. These results will be used to select a dosing schedule for CytoGam efficacy trials expected to begin in fall, 1992.
 CytoGam has been approved by the U.S. Food and Drug Administration for the prevention of primary CMV disease in kidney transplant patients. A multicenter clinical trial using CytoGam to prevent CMV in liver transplant patients was also recently completed and results will be submitted to the FDA to expand label claims.
 CMV is found in approximately half of the adult population in the United States, typically with no medical significance. In patients that are immune compromised, however, such as organ transplant recipients or AIDS patients, CMV can cause severe pneumonia, digestive tract ulcers and retinitis. In about 30 percent of AIDS patients CMV is recognized as a major contributor to death.
 MedImmune, Inc. was founded in 1988 to develop, manufacture and market therapeutics and vaccines for the treatment and prevention of infectious diseases and cancer. The company's corporate headquarters is in Gaithersburg.
 -0- 3/31/92
 /CONTACT: Franklin H. Top, Jr. M.D., executive vice president and medical director of MedImmune, Inc. 301-417-0770; or Fredric Spar of Kekst and Company, 212-593-2655, for MedImmune/
 (MEDI) CO: MedImmune, Inc. ST: Maryland IN: MTC SU:


AH -- NY070 -- 3448 03/31/92 13:20 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 31, 1992
Words:308
Previous Article:DAN D. CERUTTI JOINS WANG AS VICE PRESIDENT
Next Article:DETROIT EDISON POWER PLANTS RECORD BEST-EVER AVAILABILITY
Topics:


Related Articles
MEDIMMUNE'S CEO REVIEWS RECENT DEVELOPMENTS
MEDIMMUNE TO ACQUIRE DISTRIBUTION RIGHTS TO CYTOGAM(TM)
MEDIMMUNE ENTERS DISTRIBUTION AGREEMENT FOR CYTOGAM IN EASTERN EUROPE AND FORMER U.S.S.R.
MEDIMMUNE COMPLETES PATIENT ACCRUAL IN RSVIG-IV (RESPIGAM) TRIALS; TWO PHASE 3 TRIALS TO BE COMPLETED FOLLOWING WINTER RSV SEASON
MEDIMMUNE AND BIOTRANSPLANT FORM STRATEGIC ALLIANCE TO DEVELOP ANTI-REJECTION PRODUCTS FOR TRANSPLANTATION
MEDIMMUNE REPORTS THAT RESPIRATORY SYNCYTIAL VIRUS IMMUNE GLOBULIN INTRAVENOUS (HUMAN)(RSV-IGIV) IS ON DECEMBER AGENDA FOR REVIEW OF BLOOD PRODUCTS...
MedImmune Expands International Commercialization of CytoGam(R)
MedImmune and BioTransplant Announce Clinical Results at American Society of Transplantation Meeting.
MedImmune to Sell CytoGam(R) to ZLB Behring.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters